University says partnership ensures 30-plus early-stage startups under JLabs can continue their work.The University of Toronto (U of T) has found a new partner to operate the life sciences lab space that pharmaceutical giant Johnson & Johnson left behind last year. Cambridge, Mass.-based BioLabs is adding the space, which sits inside MaRS Discovery District, to its global network of shared labs and co-working spaces—its first in Canada. U of T says the 40,000-square-foot space is Toronto’s largest shared l ...

Key Takeaways Viatris beat Q4 estimates with 57-cent EPS and $3.7B in revenue, up 5% year over year.VTRS saw 8% operational growth in Emerging Markets and Greater China, lifting Brands sales 8%.Viatris guided 2026 revenue to $14.4B-$14.9B and EPS of $2.33-$2.47 after FDA updates.Viatris Inc. (VTRS) delivered fourth-quarter 2025 adjusted earnings per share (EPS) of 57 cents, which beat the Zacks Consensus Estimate of 52 cents. The company recorded an adjusted EPS of 54 cents in the year-ago quarter.Total rev ...

Key Takeaways ALKS delivered Q4 earnings and revenue beat, though total sales fell 10.6% year over year.ALKS saw Lybalvi sales jump 22%, while manufacturing and royalty revenues sank 43% Y/Y in Q4.ALKS named Blair Jackson CEO from August 2026 and guided 2026 revenues to be $1.73-$1.84B.Alkermes plc (ALKS) reported adjusted earnings from continuing operations of 46 cents per share for the fourth quarter of 2025, which beat the Zacks Consensus Estimate of 43 cents. The company registered earnings of $1.04 per ...

Achieved full-year profitability and positive cash flow within nine months of the VYKAT XR launch, driven by strong adoption in the PWS market. Captured approximately 12.5% of the addressable U.S. market by year-end, with 859 patients on active treatment and 1,250 total start forms received. Attributed durable growth to high prescriber engagement, with 630 unique prescribers and significant utilization across both pediatric and adult (ages 27-45) populations. Maintained a real-world safety profile c ...

Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw materials based in the Netherlands. Pharmavit Europe supplies high- ...

Key TakeawaysUS 30-year fixed mortgage rates fell to 5.98%, dropping below the 6% threshold for the first time since September 2022.The US Navy’s 5th Fleet in Bahrain has been reduced to mission-critical staffing of under 100 personnel amid escalating tensions and potential strikes involving Iran.The US International Trade Commission (ITC) launched a fact-finding probe to assess the economic impact of revoking China's Permanent Normal Trade Relations (PNTR) status.Bayer (BAYRY) reported that its PEACE-3 tri ...

"Company†) (NASDAQ: NAVN) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company's October 31, 2025 initial public offering (the "IPO†or the "Offering†). Navan investors ha...## Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Lakeland Industries, Inc. (LAKE) Shareholders To Inquire About Securities Fraud Class ActionLOS ANGELES--([BUSINESS WIRE])--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder right ...

Grifols doubles net profit in 2025, driven by revenues | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of the Spanish pharmaceuticals company Grifols is pictured on theirs facilities in Parets del Valles, north of Barcelona, Spain, January 9, 2024. REUTERS/Albert Gea [Purchase Licensing Rights, opens new tab]- Companies[Grifols SA]FollowBARCELONA, Feb 26 (Reuters) - Spanish drugmaker Grifols [(GRLS.MC), opens new tab] repo ...

Key Takeaways MIRM reported Q4 loss of 11 cents, but revenues beat estimates, rising 50% Y/Y to $148.9M.MIRM Q4 2025 sales were driven by Livmarli and newly acquired Cholbam and Ctexli products.MIRM guides 2026 net product sales of $630-$650M, eyes positive cash flow in 2027.Mirum Pharmaceuticals (MIRM) reported a loss of 11 cents per share in fourth-quarter 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company reported a loss of 49 cents per share in the year-ago quarter.Revenues i ...

Key Takeaways IRWD posted Q4 loss and revenue miss, with sales down 47% and shares sliding 11%.Ironwood's Linzess profit share declined 49% as U.S. net sales dropped 27% Y/Y in Q4 2025.IRWD reaffirmed 2026 revenue outlook of $450M-$475M and continues to see EBITDA above $300M.Ironwood Pharmaceuticals (IRWD) reported an adjusted loss of 1 cent per share for the fourth quarter of 2025, against the Zacks Consensus Estimate of earnings of 2 cents. The company had reported adjusted earnings of 1 cent per share i ...